SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Dengue vaccine trial aims to protect vulnerable patients
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether a live attenuated dengue vaccine (Butantan-DV) is safe and works well in people aged 12–59 with autoimmune rheumatic diseases like rheumatoid arthritis or lupus, who are stable on low or no immune-suppressing drugs. Participants receive one shot and are m…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells take on autoimmune diseases in first human test
Disease control Recruiting nowThis early-phase study tests a new treatment called HBI0101, which uses a patient's own immune cells modified to target and destroy faulty B cells that cause autoimmune diseases. The study includes up to 120 adults with conditions like lupus, multiple sclerosis, or rheumatoid art…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 16, 2026 20:04 UTC
-
New lupus drug PIT565 enters human safety trials
Disease control Recruiting nowThis early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Lupus trial tests NAD+ booster to tame immune system
Disease control Recruiting nowThis study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New lupus shot shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental injection called SG301 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if it can reduce disease activity better than a placebo. About 120 adults whose lupus is not well controlled by standard tr…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Could a cancer drug calm lupus in kids? new trial begins
Disease control Recruiting nowThis early-stage trial tests whether blinatumomab, a drug used for certain blood cancers, can help children with severe lupus that hasn't responded to other treatments. Six participants will receive two short courses of the drug and be followed for a year. The main goals are to s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New cell therapy aims to tame stubborn lupus and muscle inflammation
Disease control Recruiting nowThis early-stage study tests a new treatment called LUCAR-G79D for adults with lupus or inflammatory myopathies that have not responded to standard therapies. The treatment uses specially modified immune cells to target and potentially calm the overactive immune system. The main …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty immune cells that drive lupus. The main goals are to check …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New lupus drug YK012 enters human trials – hope for better disease control
Disease control Recruiting nowThis study tests a new medicine, YK012, in about 189 adults with moderate to severe lupus. The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well their lupus responds.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Engineered immune cells take on lupus in first human safety trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called universal CD19/20 CAR-T cells for 12 adults with moderate-to-severe lupus that hasn't improved with standard therapies. The main goals are to check safety, find the right dose, and see if the treatment can reduce lupus symp…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Experimental cell therapy targets severe autoimmune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and whether the treat…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New lupus drug cizutamig enters early human safety trials
Disease control Recruiting nowThis early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have ac…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Experimental immune reset: could a single infusion tame lupus and other autoimmune attacks?
Disease control Recruiting nowThis early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting the immune cells that cause the dama…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New cell therapy hopes to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed cells. The main goal is …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Global study tracks Real-World lupus drug performance
Disease control Recruiting nowThis study follows 200 adults with systemic lupus erythematosus (SLE) who are starting anifrolumab as part of their normal treatment. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time using standard checklists and patient questionnai…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune response…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New 'Biological CAR-T' drug aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus and rheumatoid arthritis that haven't responded to standard treatments. CC312 works like a 'biological CAR-T' by guiding immune cells to attack and deplete faulty B…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New shot for lupus enters early human testing
Disease control Recruiting nowThis study tests a new injection called DB-2304 in healthy people and those with lupus (SLE or CLE). The main goal is to check safety and side effects. About 148 adults will take part. This is an early-stage trial to see if the drug is safe enough for further testing.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests a new drug called SSGJ-626 in people with systemic lupus erythematosus (SLE), an autoimmune disease. The drug targets a protein on certain immune cells to possibly control the disease. About 198 adults aged 18-70 with SLE will receive either the drug or a placebo…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new medicine called SAR448501/DR-0201 in people with lupus or rheumatoid arthritis. The goal is to find the best dose and check if it is safe. About 62 adults will take part, and the study lasts about 13 months, with extra monitoring until immune ce…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called BZE2204, which uses a patient's own immune cells modified to target and attack faulty immune cells causing autoimmune diseases. It is for 20 adults with lupus, idiopathic inflammatory myopathies, or immune thrombocytopenia that …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Could CAR t cells tame lupus in young people?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teenagers and young adults (ages 12-29) with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The g…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Could a single injection tame raging autoimmune diseases?
Disease control Recruiting nowThis early-stage study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The treatment uses a special injection to reprogram the body's own T cells to target and destroy faulty B cells, aim…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Lupus patients get continued access to promising drug in new study
Disease control Recruiting nowThis study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished earlier studies. It aims to keep managing the disease long-term. Only 35 participants who are likely to benefit and meet safety criteria can join.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New drug VIS171 tested for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called VIS171 in 30 people with autoimmune diseases like lupus, alopecia areata, or a kidney condition. Participants receive the drug as a shot under the skin along with their usual treatments. The study lasts up to a year and…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
New lupus kidney trial aims to ditch steroids without sacrificing control
Disease control Recruiting nowThis study tests whether a new drug combination (obinutuzumab plus mycophenolate mofetil) can control lupus-related kidney inflammation without the need for oral steroids. About 196 people with active lupus nephritis will be randomly assigned to either the standard steroid-based …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
Could umbilical cord stem cells tame lupus? new trial launches
Disease control Recruiting nowThis early-stage study tests a single injection of stem cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can improve kidney function and reduce disease activity. Participants continue their usual medications and ar…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CHT101 for people with lupus that has not responded to standard therapies. CHT101 uses specially engineered immune cells (CAR-T cells) to target and attack the faulty cells causing the disease. The study will enroll 15 participa…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
Experimental cell therapy aims to tame Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard treatments. Participants receive a single infusion of these specially engineered cells. The main goal is to che…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
Immune cell therapy offers hope for kids with Tough-to-Treat rheumatic diseases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) for children aged 5 and older with severe rheumatic diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells are safe and can help control the diseas…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 02, 2026 11:59 UTC
-
Could CAR T-Cells tame tough lupus? new trial begins
Disease control Recruiting nowThis early-stage trial tests whether a patient's own immune cells, modified to target CD19, can safely control severe lupus that hasn't responded to standard treatments. About 18 people aged 3 to 65 with lupus or lupus kidney disease will receive the therapy and be monitored for …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC
-
New biologic combo shows promise for lupus kidney patients
Disease control Recruiting nowThis study compares two newer biologic drugs (belimumab and telitacicept) against the standard treatment (mycophenolate mofetil) for people with active lupus kidney disease. About 50 adults with biopsy-confirmed lupus nephritis will receive one of three treatment plans for six mo…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC
-
CAR-T therapy takes on autoimmune diseases: new hope for lupus and scleroderma?
Disease control Recruiting nowThis early-stage study tests a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC
-
Simple neck scan could save hearts of arthritis patients
Prevention Recruiting nowThis study tests whether using a carotid ultrasound (a neck scan) can better prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and lupus. These patients have a higher heart ris…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Instituto de Investigación Marqués de Valdecilla • Aim: Prevention
Last updated Jun 15, 2026 18:57 UTC
-
Join the lupus registry from home – no visits needed!
Knowledge-focused Recruiting nowThis study is a long-term online registry for people with lupus (including children and adults). Participants fill out surveys every six months about their symptoms, treatments, and quality of life. The goal is to collect real-world data to improve care and guide future research.…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:53 UTC
-
Heart scans aim to spot hidden risks in kids with lupus
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound. The goal is to identify which children are at higher risk for heart issues. No new treatments are being tested.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC
-
Lupus drug may harm ovaries – new study seeks answers
Knowledge-focused Recruiting nowThis study looks at whether a medicine called GnRHa can help protect the ovaries of women with lupus who are taking a strong drug called cyclophosphamide. Researchers will survey 100 women under 40 about their periods, pregnancies, and fertility history, and review their medical …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:04 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC
-
Massive lupus registry launches to unlock disease secrets
Knowledge-focused Recruiting nowThis study is creating a large registry and biorepository for 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Researchers will collect medical data and biological samples over time to better understand the dis…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:02 UTC